Pictet Asset Management Holding SA cut its stake in shares of Disc Medicine, Inc. (NASDAQ:IRON – Free Report) by 67.2% during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 126,233 shares of the company’s stock after selling 259,142 shares during the period. Pictet Asset Management Holding SA’s holdings in Disc Medicine were worth $8,263,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Arizona State Retirement System lifted its position in shares of Disc Medicine by 2.4% during the second quarter. Arizona State Retirement System now owns 6,844 shares of the company’s stock worth $501,000 after purchasing an additional 160 shares in the last quarter. AlphaCentric Advisors LLC boosted its stake in shares of Disc Medicine by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock valued at $254,000 after purchasing an additional 216 shares during the period. State of Wyoming purchased a new position in shares of Disc Medicine in the second quarter valued at $25,000. Entropy Technologies LP boosted its stake in shares of Disc Medicine by 9.9% in the first quarter. Entropy Technologies LP now owns 4,788 shares of the company’s stock valued at $306,000 after purchasing an additional 431 shares during the period. Finally, Allworth Financial LP acquired a new stake in Disc Medicine during the 2nd quarter valued at $46,000. 83.70% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Disc Medicine
In other Disc Medicine news, insider William Savage sold 16,035 shares of the business’s stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $85.09, for a total transaction of $1,364,418.15. Following the completion of the transaction, the insider directly owned 63,445 shares of the company’s stock, valued at $5,398,535.05. The trade was a 20.17% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jonathan Yu sold 8,796 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total transaction of $731,123.52. Following the completion of the transaction, the chief operating officer owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 150,277 shares of company stock valued at $11,877,059 in the last ninety days. Company insiders own 3.76% of the company’s stock.
Wall Street Analyst Weigh In
IRON has been the topic of a number of recent analyst reports. Wedbush boosted their price objective on shares of Disc Medicine from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, October 19th. BMO Capital Markets raised their target price on Disc Medicine from $100.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Wall Street Zen upgraded Disc Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Thursday, October 15th. Finally, Cantor Fitzgerald boosted their price target on Disc Medicine from $125.00 to $170.00 and gave the stock an “overweight” rating in a research note on Monday, October 19th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Disc Medicine has an average rating of “Moderate Buy” and an average price target of $124.18.
Read Our Latest Report on IRON
Disc Medicine Price Performance
Shares of NASDAQ:IRON opened at $80.00 on Monday. The stock has a market capitalization of $3.64 billion, a price-to-earnings ratio of -12.62 and a beta of 0.96. Disc Medicine, Inc. has a 1-year low of $40.00 and a 1-year high of $99.50. The company’s fifty day moving average is $71.60 and its two-hundred day moving average is $71.07. The company has a debt-to-equity ratio of 0.10, a quick ratio of 20.30 and a current ratio of 20.30.
Disc Medicine (NASDAQ:IRON – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($1.53) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.10. Equities analysts anticipate that Disc Medicine, Inc. will post -6.20 EPS for the current year.
About Disc Medicine
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.
Further Reading
- Five stocks we like better than Disc Medicine
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding IRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Disc Medicine, Inc. (NASDAQ:IRON – Free Report).
Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
